We look forward to presenting scientific insights about our SARM1 inhibitor and RIPK1 inhibitor at the upcoming Society for Neuroscience conference in San Diego! https://bit.ly/3Lo6xoI
Sironax
Biotechnology
Waltham, Massachusetts 2,291 followers
Transformative therapies for degenerative diseases affecting longevity
About us
Sironax is a global clinical-stage biotechnology company committed to promoting healthier aging by discovering and developing novel treatments for degenerative diseases affecting longevity, diseases requiring supportive care, and certain autoimmune immunology and inflammation diseases. Sironax has three proprietary clinical-stage programs with first-in-class or best-in-class assets, and several undisclosed preclinical programs. The company’s research targets key contributors of aging: dysregulated cellular death, uncontrolled inflammation, and disrupted energy homeostasis. Sironax is headquartered in Waltham, Massachusetts, with comprehensive research centers in Beijing and Shanghai, China, and additional operations in Basel, Switzerland and Sydney, Australia. For more information, visit sironax.com.
- Website
-
https://www.sironax.com/
External link for Sironax
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Degenerative diseases, Inflammatory diseases, Muscular disorders, Metabolic disorders, and Neurodegenerative diseases
Locations
Employees at Sironax
-
Kevin Wagner
Astounding Executive / Personal Assistant to C-suite, former oenophile, and all-around fixer
-
Erik Kopp
Corporate Communications Leader
-
Meghan O'Connell
Seasoned Quality leader and mentor delivering Quality-as-a-Service in pharma, biotech, and medical devices ♦ GxP/GMP/GCP/GLP
-
Libin Shang
VP of BD, CorpComm, and BeijingOps at Sironax
Updates
-
We are happy to welcome Dr. Nasir Khan and Dr. Gary Ingenito to Sironax! They have joined our global team to help advance our drug discovery and development. http://bit.ly/4hwgIUc
-
-
At Sironax, we are studying the role of RIPK1 in regulating cell death and inflammation for novel therapeutic approaches. Together, we are developing transformative treatments for age-related degenerative diseases. http://bit.ly/3JbkG7P
-
At Sironax, we are developing transformative treatments for age-related degenerative diseases. Explore the critical role of NAMPT in energy homeostasis and the therapeutic potential of NAMPT activator in muscular degenerative diseases. http://bit.ly/3KE3AzX
-
At Sironax, we are developing transformative treatments for age-related degenerative diseases. Explore the role of SARM1 in axonal degeneration and the therapeutic potential of SARM1 inhibition in neurodegenerative diseases. http://bit.ly/4gzDQjW
-
Members of our U.S. leadership team were thrilled to join our President and CEO, Dr. Shefali Agarwal, at the Endpoints 11 gala in Boston. It’s an honor for Sironax to be recognized as one of the most promising biotech startups of 2025! http://bit.ly/4n4sMhg
-
-
We are delighted to be honored by Endpoints News as one of the most promising biotech startups in their Endpoints 11 list for 2025. Thank you, Endpoints News, for recognizing our commitment to developing transformative treatments for age-related degenerative diseases. http://bit.ly/4n4sMhg
-
-
At Sironax, we are developing transformative therapies for degenerative diseases affecting longevity. Our President and CEO, Dr. Shefali Agarwal (center), recently joined our Beijing leadership team, local colleagues, and employees around the world for an all-hands meeting. Together, we are "Gathering Strength, Shaping the Future: One Team to Care and Deliver." https://bit.ly/3UytNkX
-
-
At Sironax, we are proud of our 160-member team, based in Waltham, Beijing, Shanghai, Basel, and Sydney. Together, we are discovering and developing novel treatments for degenerative diseases affecting longevity, diseases requiring supportive care, and certain immunology and inflammation diseases. https://bit.ly/3UytNkX
-
-
At Sironax, our research targets key contributors of aging: dysregulated cell death, uncontrolled inflammation, and disrupted energy homeostasis. We have three proprietary clinical-stage programs, consisting of four first-in-class or best-in-class assets, and several undisclosed preclinical programs that have come from these efforts. Learn more. https://bit.ly/3UytNkX
-